Dupixent

News

COPD patients will get access to Dupixent via NHS

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

News

China clears GSK's Nucala for COPD

GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

GSK claims first approval for Nucala in COPD

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.

News

GSK sets up Nucala and Dupixent showdown in COPD

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.

COPD patients will get access to Dupixent via NHS

China clears GSK's Nucala for COPD

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Dupixent is first FDA-approved drug for rare skin disease

GSK claims first approval for Nucala in COPD

GSK sets up Nucala and Dupixent showdown in COPD

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Dupixent

Editor's Picks